|
|
|
|
A first-in-class orally available HBV cccDNAdestabilizer ccc_R08 achieved sustainable HBsAg and cccDNA reduction in the HBVcircle mouse model
|
|
|
Reported by Jules Levin
EASL 2019 Vienna April
1Li Wang, 1QihuiZhu, 1Jing Zeng,1 ZhipengYan,1Song Feng, 2John A. T. Young, and 1Lu Gao
1Roche Innovation Centre Shanghai, Shanghai, China; 2. Roche Innovation Centre Basel, Basel, Switzerland
|
|
|
|
|
|
|